Breaking News

Otsuka Acquires Rights to Eisai’s Dacogen

March 31, 2014

Gains development and commercialization rights in the U.S., Canada and Japan

Eisai, Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., has sold the rights to DACOGEN (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd. DACOGEN is approved for treatment of patients with myelodysplastic syndromes
Through an exclusive worldwide license, Otsuka gains full development and commercialization rights for the product in the former Eisai territories of the U.S., Canada and Japan. Eisai will retain its rights for DACOGEN in Mexico. Otsuka will also gain the patent for Eisai’s metabolic enzyme inhibitor E7727.
Eisai's marketing rights for DACOGEN originate from a worldwide license from Astex Pharmaceuticals, Inc., which was acquired by Otsuka in October 2013.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.